Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

Roche has tak­en its next big step in­to the al­lo­gene­ic CAR-T field, this time ty­ing up along­side Po­sei­da Ther­a­peu­tics $PSTX with $220 mil­lion in up­front and quick cash in a trade­mark on­col­o­gy al­liance that comes with a moth­er lode of mile­stones.

The deal — which in­cludes $110 mil­lion for the up­front plus $110 mil­lion in near-term cash — of­fers the phar­ma gi­ant dibs on a slate of off-the-shelf CAR-Ts for hema­to­log­ic ma­lig­nan­cies, in­clud­ing P-BC­MA-AL­LO1 for mul­ti­ple myelo­ma, now in a Phase I study, and P-CD19CD20-AL­LO1, an al­lo­gene­ic dual CAR-T for the treat­ment of B-cell ma­lig­nan­cies with an IND ex­pect­ed in 2023. But they will al­so work on more tar­gets to­geth­er — ham­mer­ing out new re­search tech along the way — as the Po­sei­da team takes the lead on ear­ly-stage tests and Roche carves out re­spon­si­bil­i­ty for the piv­otal plays.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER